Guggenheim Reaffirms “Buy” Rating for Centessa Pharmaceuticals (NASDAQ:CNTA)

Centessa Pharmaceuticals (NASDAQ:CNTA)‘s stock had its “buy” rating reaffirmed by equities research analysts at Guggenheim in a research report issued to clients and investors on Wednesday,Benzinga reports. They currently have a $28.00 target price on the stock. Guggenheim’s target price points to a potential upside of 92.97% from the company’s current price.

CNTA has been the topic of several other research reports. TD Cowen began coverage on shares of Centessa Pharmaceuticals in a research report on Tuesday, January 7th. They set a “buy” rating on the stock. Morgan Stanley reaffirmed an “overweight” rating and set a $27.00 price objective on shares of Centessa Pharmaceuticals in a research report on Friday, March 7th. Seven research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the company currently has a consensus rating of “Buy” and an average target price of $26.00.

Centessa Pharmaceuticals Trading Down 0.2 %

Shares of Centessa Pharmaceuticals stock opened at $14.51 on Wednesday. The stock’s 50 day simple moving average is $16.49 and its 200-day simple moving average is $16.41. The stock has a market cap of $1.91 billion, a P/E ratio of -9.48 and a beta of 1.54. The company has a debt-to-equity ratio of 0.15, a current ratio of 21.52 and a quick ratio of 21.52. Centessa Pharmaceuticals has a 1-year low of $7.75 and a 1-year high of $19.09.

Centessa Pharmaceuticals (NASDAQ:CNTA) last posted its quarterly earnings results on Monday, March 24th. The company reported ($0.34) EPS for the quarter, topping the consensus estimate of ($0.38) by $0.04. Analysts predict that Centessa Pharmaceuticals will post -1.6 EPS for the current fiscal year.

Insider Transactions at Centessa Pharmaceuticals

In other Centessa Pharmaceuticals news, insider Gregory M. Weinhoff sold 11,742 shares of the business’s stock in a transaction on Monday, January 27th. The shares were sold at an average price of $16.47, for a total value of $193,390.74. Following the completion of the transaction, the insider now owns 159,782 shares in the company, valued at $2,631,609.54. The trade was a 6.85 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, insider David M. Chao sold 7,000 shares of the company’s stock in a transaction on Monday, March 17th. The stock was sold at an average price of $17.17, for a total value of $120,190.00. Following the sale, the insider now directly owns 225,007 shares in the company, valued at $3,863,370.19. This represents a 3.02 % decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 260,168 shares of company stock valued at $4,309,568. 11.59% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently bought and sold shares of CNTA. GF Fund Management CO. LTD. acquired a new stake in Centessa Pharmaceuticals in the 4th quarter valued at about $31,000. GAMMA Investing LLC increased its stake in shares of Centessa Pharmaceuticals by 29.1% during the fourth quarter. GAMMA Investing LLC now owns 3,837 shares of the company’s stock worth $64,000 after buying an additional 865 shares during the period. Barclays PLC raised its holdings in Centessa Pharmaceuticals by 1,414.9% in the fourth quarter. Barclays PLC now owns 5,302 shares of the company’s stock valued at $89,000 after acquiring an additional 4,952 shares in the last quarter. BNP Paribas Financial Markets acquired a new stake in Centessa Pharmaceuticals in the fourth quarter valued at approximately $162,000. Finally, OMERS ADMINISTRATION Corp purchased a new position in Centessa Pharmaceuticals in the fourth quarter worth approximately $171,000. 82.01% of the stock is currently owned by hedge funds and other institutional investors.

About Centessa Pharmaceuticals

Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines for patients. Its products pipeline includes SerpinPC, an activated protein C inhibitor for the treatment of hemophilia A and B; and ORX750, an orally administered OX2R agonist for the treatment of narcolepsy and other sleep disorders.